Fig. 5.

Compromised exosome release leads to sparsely innervated tumors. a Neurite outgrowth of PC12 cells following exosome stimulation from the indicated sources. Stimulation with recombinant NGF (100 ng/ml) serves as a positive control. n = 4 technical replicates/condition; experiment repeated at least three times with biological replicates. Statistical analysis by one-way ANOVA with post hoc Fisher’s Least Significant Difference (LSD) test. LSD p values reported; *p ≤ 0.02. The variance between groups compared is similar. Central value used is the mean. All comparisons and p values found in Supplementary Table 4. b Western blot analysis of whole tumor lysate from mice bearing mEERL parental or Rab27A^−/+Rab27B^−/− tumors. n = 3 technical replicates. n = 4 biological replicates. Western blots have been cropped for clarity and conciseness. Western blot quantification by densitometry for c β-III tubulin, *p<0.05; d Tau, *p<0.0001; and e TRPV1, *p<0.001. Statistical analysis by unpaired, two-tailed Student’s t-test. Central value used was the mean. The variance between groups compared is similar. f Nanoparticle tracking analysis of exosomes purified from the plasma of tumor bearing mice treated with GW4869 or vehicle. Statistical analysis by two-tailed Student’s t-test. Central value used was the mean. The variance between groups compared is similar; *p<0.0001. g Quantification of β-III tubulin IHC staining of tumors from mice (n = 7/group) treated with GW4869 or vehicle; Statistical analysis by unpaired, two-tailed Student’s t-test; *p<0.05. Central value used was the mean. Experiment performed once. The variance between groups compared is similar. h En face bright field representative images of IHC for β-III tubulin of mEERL tumors treated with GW4869 or vehicle. n = 7/group. Scale bar, 100 µm. All error bars are standard deviation